Skip to main content
Retour
NBIX logo

Neurocrine Biosciences, Inc.

Qualité des données : 100%
NBIX
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
127,86 €
▲ 0,81 € (0,64%)
Cap. Boursière : 12,83B
Fourchette du Jour
125,11 € 128,31 €
Fourchette 52 Semaines
84,23 € 160,18 €
Volume
1 007 922
Moyenne 50J / 200J
132,64 € / 136,96 €
Clôture Précédente
127,05 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 26,8 0,3
P/B 3,9 2,9
ROE % 16,4 3,7
Net Margin % 16,7 3,8
Rev Growth 5Y % 26,0 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
170,36 € +33.2%
Low: 140,00 € High: 195,00 €
P/E Prévisionnel
21,5
BPA Prévisionnel
5,91 €
Croissance BPA (est.)
+0,0%
CA Est.
3,4 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 12,44 €
11,26 € – 15,00 €
 4,6 B 14
FY2029 10,61 €
9,61 € – 12,79 €
 4,3 B 14
FY2028 10,03 €
5,64 € – 16,15 €
 4,2 B 16

Points Clés

Revenue grew 26,04% annually over 5 years — strong growth
Earnings grew 40,23% over the past year
ROE of 16,38% — decent returns on equity
Net margin of 16,73% shows strong profitability
Debt/Equity of 0,13 — conservative balance sheet
Generating 748,70M in free cash flow

Croissance

Revenue Growth (5Y)
26,04%
Revenue (1Y)21,45%
Earnings (1Y)40,23%
FCF Growth (3Y)43,89%

Qualité

Return on Equity
16,38%
ROIC12,66%
Net Margin16,73%
Op. Margin21,64%

Sécurité

Debt / Equity
0,13
Current Ratio3,39
Interest Coverage0,00

Valorisation

P/E Ratio
26,81
P/B Ratio3,94
EV/EBITDA20,25
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 21,45% Revenue Growth (3Y) 23,12%
Earnings Growth (1Y) 40,23% Earnings Growth (3Y) 38,44%
Revenue Growth (5Y) 26,04% Earnings Growth (5Y) 52,03%
Profitability
Revenue (TTM) 2,86B Net Income (TTM) 478,60M
ROE 16,38% ROA 10,33%
Gross Margin 98,18% Operating Margin 21,64%
Net Margin 16,73% Free Cash Flow (TTM) 748,70M
ROIC 12,66% FCF Growth (3Y) 43,89%
Safety
Debt / Equity 0,13 Current Ratio 3,39
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 26,81 P/B Ratio 3,94
P/S Ratio 4,49 PEG Ratio 0,71
EV/EBITDA 20,25 Dividend Yield 0,00%
Market Cap 12,83B Enterprise Value 12,53B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,86B 2,36B 1,89B 1,49B 1,13B
Net Income 478,60M 341,30M 249,70M 154,50M 89,60M
EPS (Diluted) 4,67 3,29 2,47 1,56 0,92
Gross Profit 2,81B 2,32B 1,85B 1,47B 1,12B
Operating Income 619,10M 570,50M 250,90M 249,00M 102,50M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4,63B 3,72B 3,25B 2,37B 2,07B
Total Liabilities 1,38B 1,13B 1,02B 660,90M 698,50M
Shareholders' Equity 3,25B 2,59B 2,23B 1,71B 1,37B
Total Debt 415,30M 455,10M 428,40M 262,90M 440,40M
Cash & Equivalents 713,00M 233,00M 251,10M 262,90M 340,80M
Current Assets 2,52B 1,72B 1,61B 1,45B 972,80M
Current Liabilities 743,40M 507,70M 654,80M 537,70M 245,80M

Scores de Stratégies

This stock passed the criteria for 6 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#761 of 1052
34
Custom Capital Light Compounder
#211 of 218
17
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#120 of 332
56
Custom Full Throttle
#90 of 146
38
Custom Balanced Risk
#56 of 151
50
Custom Lower Risk
#90 of 140
42

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026
Entré Capital Light Compounder
Mar 24, 2026
Entré Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Entré Full Throttle
Mar 24, 2026
Entré Balanced Risk
Mar 24, 2026
Entré Lower Risk
Mar 24, 2026